⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARMP News
Armata Pharmaceuticals, Inc. Common Stock
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
ARMP
GILD
Form 8-K
sec.gov
ARMP
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
prnewswire.com
ARMP
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
prnewswire.com
ARMP
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
prnewswire.com
ARMP
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
prnewswire.com
ARMP
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
prnewswire.com
ARMP
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
prnewswire.com
ARMP
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
prnewswire.com
ARMP